RB1 and adenocarcinoma: Future studies can test whether LSD1 inhibition combined with EGFR inhibitors could prevent trans-differentiation to SCLC in patients with EGFR-Mutant adenocarcinoma, which could be particularly beneficial for EGFR-Mutant adenocarcinomas with concurrent RB1 and TP53 mutations that are at higher risk for SCLC trans-differentiation50.